Rac/Cdc42-IN-1

Overview

Rac/Cdc42-IN-1, the major phase I metabolite of the oral Rac/Cdc42 inhibitor MBQ-167 ( HY-112842 ) in vivo , is a selective Rac inhibitor. Rac/Cdc42-IN-1 functions by blocking the GTP-binding activation of Rac1, targeting the autophosphorylation of Thr 423 /Thr 402 /Thr 436 and Ser 141 /Ser 144 /Ser 154 in downstream PAK1/2/3 , with an inhibitory effect superior to that of MBQ-167 . Rac/Cdc42-IN-1 significantly inhibits cell migration, and suppresses tumor growth and distant metastasis to the lung, liver and kidney in HER2+ breast cancer mouse models. Rac/Cdc42-IN-1 can be used for targeted research on metastatic breast cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > PAK | Products > Signaling Pathways > Cdc42-binding kinase

Product Information

• Catalog No.: HY-183246
• CAS No.: 2143950-05-2
• Molecular Formula: C20H14N4
• Molecular Weight: 310.35
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source